Gentium hopes latest defibrotide response will convince EMA
04:20 EDT 22 Jun 2012 | SCRIP
Gentium says it has submitted its responses to the Day 180 list of outstanding issues that it received from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) with respect to its marketing authorisation.....
Original Article: Gentium hopes latest defibrotide response will convince EMA
More From BioPortfolio on "Gentium hopes latest defibrotide response will convince EMA"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
